CNBC·2 min read·medium
Novo Nordisk sues Eli Lilly, alleging misleading GLP-1 advertising - CNBC
A
Annika Kim Constantino
✦AI Summary
Novo Nordisk has initiated a lawsuit against Eli Lilly regarding the marketing of their respective GLP-1 obesity and diabetes medications. The suit claims that Eli Lilly's advertising campaigns are intentionally misleading consumers about the efficacy and superiority of their products.
Novo Nordisk on Tuesday filed a lawsuit against Eli Lilly, alleging that its advertising campaigns for its blockbuster obesity and diabetes drugs are designed to mislead consumers about their superio…
businesshealth
✦
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in